These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22129679)

  • 1. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.
    Kaja S; Hilgenberg JD; Everett E; Olitsky SE; Gossage J; Koulen P
    Hum Antibodies; 2011; 20(3-4):95-101. PubMed ID: 22129679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary hemorrhagic telangiectasia/avastin.
    Davidson TM; Olitsky SE; Wei JL
    Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
    Alderman C; Corlett J; Cullis J
    Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
    Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
    J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
    Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
    Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
    Karnezis TT; Davidson TM
    Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
    Fleagle JM; Bobba RK; Kardinal CG; Freter CE
    Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
    Dupuis-Girod S; Ambrun A; Decullier E; Fargeton AE; Roux A; Bréant V; Colombet B; Rivière S; Cartier C; Lacombe P; Chinet T; Blivet S; Blondel JH; Gilbert-Dussardier B; Dufour X; Michel J; Harle JR; Dessi P; Faure F
    JAMA; 2016 Sep; 316(9):934-42. PubMed ID: 27599328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.
    Guldmann R; Dupret A; Nivoix Y; Schultz P; Debry C
    Laryngoscope; 2012 May; 122(5):953-5. PubMed ID: 22447341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In reference to hereditary hemorrhagic telangiectasia/avastin.
    Bachmann-Harildstad G
    Laryngoscope; 2010 Oct; 120(10):2134. PubMed ID: 20824638
    [No Abstract]   [Full Text] [Related]  

  • 17. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
    Rohrmeier C; Sachs HG; Kuehnel TS
    Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.